What does Serum Glycosylated Apolipoprotein J mean in a heart attack?-----Correlation of serum glycosylated apolipoprotein J with acute myocardial infarction

Abstract

AbstractBackgroundThere are few myocardial damage markers that could be used to diagnose acute myocardial infarction(AMI) or assess its severity, especially glycosylated apolipoprotein J(ApoJ-Glyc) has demonstrated superiority in cardiomyocytes and animal STEMI models in the early stages of myocardial ischemia(MI). We aimed to excavate the potential role of ApoJ-Glyc as a protein marker in the pathogenesis of AMI in humans and its added value in the evolution of the disease.Methods and ResultsELISA was used to determine the serum concentration of ApoJ-Glyc in 163 patients enrolled by the criteria. Statistical analysis could used to discuss the relationship between ApoJ-Glyc and AMI. Compared to control groups, serum ApoJ-Glyc levels decreased by 36% and 37% in early AMI patients and AMI patients, respectively (P<0.0001), showing a higher discriminant value for early diagnosis and diagnosis of AMI [area under the curve (AUC) : 0.871 and 0.886, P< 0.0001]. For the first time, we demonstrated that ApoJ-Glyc was not statistically significant in the comparative difference between NSTEMI and STEMI groups (P> 0.05). Patients with gradually declining ApoJ-Glyc had a higher Grace Risk Scores. Subsequent studies have also demonstrated that more MACCE did occur with a 6-month follow-up(P<0.05).ConclusionsApoJ-Glyc which serve as an alarm bell for the detection of early ischaemia, may be a new biomarker for AMI. ApoJ-Glyc can assess the severity of myocardial infarction. The continuous decrease of serum ApoJ-Glyc suggests an increase in the risk of post-AMI ischaemia and the onset of unpredictable MACCE.Graphic abstract